Clinical Trials Browser

Phase 2 × Bevacizumab × Thoracic × Clear all

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07001618 2026-04-03

IMMUNOLIFE2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT05263947 2026-02-24

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT07416058 2026-02-17

PHOENIX

Phase 2 Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT03896074 2026-02-09

BEAT

Phase 2 Active not recruiting

Non-small-cell Lung Cancer Patients

NCT03133546 2026-02-06

BOOSTER

Phase 2 Completed

155 enrolled 23 charts

Non Small Cell Lung Cancer Metastatic

NCT04958811 2026-01-26

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT07244926 2025-11-24

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Neoplasms

NCT05781308 2025-11-18

ADAPTABLE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05588388 2025-11-17

BELIEVE

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT07182708 2025-09-19

HOFIBREN

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT00334815 2025-08-24

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

29 enrolled 10 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

Phase 2 Not yet recruiting

NSCLC

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07083375 2025-07-24

QL1706

Phase 2 Not yet recruiting

Extensive Small Cell Lung Cancer

NCT06953843 2025-07-14

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Phase 2 Recruiting

NSCLC Stage IV Without EGFR/ALK Mutation

NCT06276283 2025-06-19

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07014215 2025-06-10

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04042558 2025-05-31

GFPC 06-2018

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04512430 2025-04-02

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Phase 2 Terminated

4 enrolled 9 charts

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04997382 2025-02-25

CLASSIC5

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Phase 2 Recruiting

Lung Neoplasms

NCT06728865 2024-12-11

Better Brain

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT03872661 2024-12-06

NIBCUN

Phase 2 Recruiting

Lung Neoplasms

NCT06683703 2024-11-12

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Phase 2 Not yet recruiting

Non-small Cell Lung Cancer Patients with Brain Metastases

NCT05468242 2024-10-30

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT00309998 2024-10-29

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05491811 2024-09-19

EAGLE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00998166 2024-07-30

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Phase 2 Terminated

12 enrolled 3 charts

Carcinoma, Non-Small-Cell Lung

NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04730999 2024-07-05

CeLEBrATE

Phase 2 Completed

Small Cell Lung Carcinoma

NCT06483347 2024-07-03

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Phase 2 Recruiting

Lung Neoplasms

NCT05284539 2024-06-07

Awesome

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05266846 2024-05-30

BEYOND

Phase 2 Recruiting

Adenocarcinoma of Lung

NCT04426825 2024-05-21

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Completed

23 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT04147351 2024-04-16

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Phase 2 Active not recruiting

NSCLC Stage IIIB~IV

NCT04310943 2024-03-06

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT04238169 2024-02-28

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06229340 2024-01-29

NТО-RAS

Phase 2 Recruiting

DermatologicGastrointestinalThoracic

Lung Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05296278 2024-01-10

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04099836 2023-12-26

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT04345146 2023-08-28

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

Phase 2 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00828009 2023-07-07

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

70 enrolled 10 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Phase 2 Unknown

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung